OSCR
Oscar Health, Inc.
OSCR has the edge over SNDA overall, supported by stronger fundamentals and stronger modeled upside.
SNDA
Sonida Senior Living, Inc.
SNDA has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Weak |
SNDA's revenue is currently strong, but its profitability, cash flow and balance sheet are weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SNDA PE Valuation
SNDA has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SNDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SNDA's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SNDA on earnings quality, reporting a profit while its opponent remains loss making.
SNDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.36 | -$2.01 |
| Q2 2026 | -$6.20 | -$3.43 |
| Q1 2026 | -$5.84 | -$2.37 |
| Q4 2025 | -$4.22 | -$3.68 |
| Q3 2025 | -$3.35 | -$1.96 |
| Q2 2025 | -$2.77 | +$0.43 |
| Q1 2025 | -$3.47 | +$0.98 |
| Q4 2024 | -$0.54 | +$3.31 |
SNDA is still losing money, but far less than before: $5.36 per share over the past year, against $134.88 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SNDA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SNDA on profitability, with a higher operating margin.
SNDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $210.2M | +114% |
| Q2 2026 | $207.6M | +122% |
| Q1 2026 | $122.6M | +33% |
| Q4 2025 | $97.7M | +6.2% |
| Q3 2025 | $98M | +31% |
| Q2 2025 | $93.5M | +33% |
| Q1 2025 | $91.9M | +36% |
| Q4 2024 | $91.9M | +40% |
SNDA's revenue has grown year over year for 18 quarters in a row: $210M last quarter, up 114% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9.3% | +6.5 points |
| Q2 2026 | -2.6% | -0.2 points |
| Q1 2026 | -24% | -46 points |
| Q4 2025 | -22% | -15 points |
| Q3 2025 | -16% | -9.2 points |
| Q2 2025 | -2.4% | -0.4 points |
| Q1 2025 | 22% | +25 points |
| Q4 2024 | -7% | -0.1 points |
SNDA's operating margin was −9.3% last quarter, up 6.5 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SNDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
SNDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.6M | +360% |
| Q2 2026 | -$3.7M | -292% |
| Q1 2026 | -$42.6M | -$38.1M |
| Q4 2025 | -$9.3M | +$1.1M |
| Q3 2025 | $3M | +$8M |
| Q2 2025 | $1.9M | +$3.6M |
| Q1 2025 | -$4.5M | +$5.4M |
| Q4 2024 | -$10.4M | -$6.6M |
SNDA has burned cash in most quarters: −$42M over the past year, against −$10M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over SNDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SNDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +821K shares |
| 1 year | +163% | +29.5M shares |
| 3 years | +649% | +41.3M shares |
| 5 years | +2077% | +45.4M shares |
SNDA has 48M diluted shares, up 163% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2022 | $44,000 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SNDA on leverage, with a lower net debt burden relative to earnings.
SNDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 32.9x | High |
| Q2 2026 | 72.2x | High |
| Q4 2025 | 18.1x | High |
| Q3 2025 | 13.0x | High |
| Q2 2025 | 11.5x | High |
| Q1 2025 | 11.5x | High |
| Q4 2024 | 21.7x | High |
| Q3 2024 | 20.8x | High |
SNDA's net debt is more than 20 years of its operating earnings (EBITDA), up from 11 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SNDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 9.7 | Oversold |
SNDA's weekly RSI is 39 (neutral) and its Stochastic is 10 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SNDA PE vs Healthcare Sector
| Metric | SNDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SNDA has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SNDA on trend strength, trading above more of its moving averages.
SNDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.0 | 5.3% below |
| 20 week MA | $37.9 | 12% below |
| 50 week MA | $35.7 | 7% below |
| 100 week MA | $30.4 | 9.1% above |
| 200 week MA | $23.7 | 40% above |
SNDA has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 40% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SNDA on returns for 2026, with the stronger performance.
SNDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.6 | $12.9 | -73% |
| 2021 | $12.9 | $28.6 | +122% |
| 2022 | $28.6 | $11.7 | -59% |
| 2023 | $11.7 | $9.66 | -17% |
| 2024 | $9.66 | $22.9 | +137% |
| 2025 | $22.9 | $32.3 | +41% |
| 2026 YTD | $32.3 | $33.2 | +2.8% |
SNDA's yearly returns have swung widely, from +137% in 2024 to −73% in 2020. It's up 2.8% so far in 2026.